Allergan, Argentum settle patent dispute over eye drug Restasis

U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan’s eye drug, Restasis.

The agreement gives Argentum the right to sell the copycat version of Restasis before the patents covering the drug expire, Argentum said. It did not disclose when it would launch the generic product.

Restasis, which was approved by the U.S. Food and Drug Administration in 2002, is used to treat dry eye.

(Reporting by Divya Grover in Bengaluru; Editing by Sai Sachin Ravikumar)

Read More at Reuters

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

No Preview
These Are the Best Walking Workouts, According to Fitness Experts
This 5-Move Dumbbell Routine Builds Strength in Every Muscle Group
Running Success Can Be Contagious, Says New Study
Get Ready for Summer With This Full-Body Workout From the Tone It Up Girls
Beauty queen uses platform to bring attention to rare genetic disorder
The Inspiring Way This Fitness Blogger Flips the Script On Negative Self-Talk
School crossing guard, 91, marks 50 years of service
Fearing disease, Kenyans burn animal carcasses as drought deepens
The Salad Trend You Didn’t Know You Needed
Leonardo DiCaprio Invests in Sustainable Seafood Line
Why Bob Harper Is Eating a Mediterranean Diet Post Heart Attack
A Foolproof Way to Grow Your Own Food (Even with a Black Thumb)
No Preview
These Are the Best Walking Workouts, According to Fitness Experts
Injured Venezuela protesters face another woe: finding medicine
U.S. top court grapples over making copycat biologics available sooner
Conservative House group says ready to back latest U.S. healthcare bill